MINIMIZING DIABETIC CARDIOVASCULAR COMPLICATIONS: THE ROLE OF RAPID- AND LONG-ACTING INSULIN IN MAINTAINING CONSISTENT GLYCEMIC CONTROL
FACULTY
Mark E. Molitch, MD
Professor of Medicine
Northwestern University
The Feinberg School of Medicine
Division of Endocrinology
Chicago, IL
PURPOSE STATEMENT
Minimizing Diabetic Cardiovascular Complications: The Role of Rapid- and Long-Acting Insulin in Maintaining Consistent Glycemic Control will discuss the impact of diabetes and uncontrolled glycemia on cardiovascular risk, and how insulin analogs can be used to maintain glycemic control in diabetic patients.
LEARNING OBJECTIVES
Upon completion of this activity, participants should be able to:
- Discuss elevated cardiovascular risk as a complication of diabetes
- Describe the value of tight glycemic control, including basal and post-prandial glucose levels, in managing cardiovascular risk
- Evaluate the role of insulin, both rapid- and long-acting analogs, in controlling glycemia in diabetic patients
TARGET AUDIENCE
Minimizing Diabetic Cardiovascular Complications: The Role of Rapid- and Long-Acting Insulin in Maintaining Consistent Glycemic Control is intended for primary healthcare professionals, including physicians, physician assistants, nurse practitioners, nurses, and pharmacists, as well as for other specialists and healthcare providers who are interested in the management of patients with diabetes.
ACCREDITATION INFORMATION
Expiration date: November 7, 2008
Physicians: MESG is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. MESG designates this educational activity for a maximum of
1.0 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Nurses (CBRN): Med-IQis a provider approved by the California Board of Registered Nursing, Provider Number CEP #14745, for 1.0 Contact Hour(s).
Pharmacists: 
1 contact hour(s). (0.100 CEUs) of credit for pharmacists. This activity co-sponsored by Medical Education Collaborative, Inc. (MEC) and Med-IQ. MEC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE #s: Webcast - # 815-999-07-024-H01, Newsletter - #815-999-07-049-H01. The program is designed for all pharmacists.
Other Credit Information
Nurse Practitioners: Med-IQ is accredited by ACCME to provide continuing medical education for physicians, and will provide nurse practitioners who successfully complete the activity with a Statement of Participation indicating that the activity was designated for 1 AMA PRA Category 1 Credit(s)TM.
Physician Assistants: The American Academy of Physician Assistants (AAPA) accepts AMA PRA Category 1 Credit(s)TM for the PRA from organizations accredited by ACCME.
Disclosure Policy
It is the policy of Med-IQ that the speaker and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during presentation(s). Individuals who refuse to disclose will be disqualified from all aspects associated with this CME activity. Med-IQ has policies in place that will identify and resolve all conflicts of interest prior to this educational activity.
MESG Disclosure
Reshma Carter has disclosed that her spouse is an employee of Novartis Pharmaceuticals.
All other employees of Med-IQ have no financial relationships to disclose.
MEC Disclosure
The employees of Medical Education Collaborative have no financial relationships to disclose.
Acknowledgement of Commercial Support
This educational series is supported by an educational grant from sanofi-aventis U.S.